SEC Filings

Form S-1
TRACON PHARMACEUTICALS, INC. filed this Form S-1 on 03/27/2017
Document Outline
Entire Document (633.2 KB)
Subdocument 1 - S-1 - S-1
Page 1 - As filed with the Securities and Exchange Commission on March 27, 2017
Page 2 - The information in this prospectus is not complete and may be changed. The selling stockholder may n
Page 3 - TABLE OF CONTENTS
Page 4 - N/A
Page 5 - PROSPECTUS SUMMARY
Page 6 - N/A
Page 7 - N/A
Page 8 - Corporate Information
Page 9 - Implications of Being an Emerging Growth Company
Page 10 - The Offering
Page 11 - N/A
Page 12 - N/A
Page 13 - RISK FACTORS
Page 14 - SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Page 15 - N/A
Page 16 - THE ASPIRE CAPITAL TRANSACTION
Page 17 - Purchase of Shares under the Purchase Agreement
Page 18 - Minimum Share Price
Page 19 - Percentage of Outstanding Shares after Giving Effect to the Purchased Shares Issued to Aspire Capita
Page 20 - USE OF PROCEEDS
Page 21 - N/A
Page 22 - PLAN OF DISTRIBUTION
Page 23 - N/A
Page 24 - LEGAL MATTERS
Page 25 - DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITY
Page 26 - 3,231,515 Shares
Page 27 - PART II
Page 28 - N/A
Page 29 - Item 15. Recent Sales of Unregistered Securities
Page 30 - (b) Stock Option and Restricted Stock Grants
Page 31 - N/A
Page 32 - SIGNATURES
Page 33 - Exhibit Index
Page 34 - N/A
Page 35 - ExhibitNumber
Subdocument 2 - EX-5.1 - EX-5.1
Page 1 - Exhibit 5.1
Page 2 - N/A
Subdocument 3 - EX-10.39 - EX-10.39
Page 1 - Exhibit 10.39
Page 2 - Table of Contents
Page 3 - Recitals
Page 4 - N/A
Page 5 - N/A
Page 6 - N/A
Page 7 - N/A
Page 8 - N/A
Page 9 - N/A
Page 10 - N/A
Page 11 - N/A
Page 12 - N/A
Page 13 - N/A
Page 14 - N/A
Page 15 - N/A
Page 16 - N/A
Page 17 - N/A
Page 18 - N/A
Page 19 - N/A
Page 20 - N/A
Page 21 - N/A
Page 22 - N/A
Page 23 - N/A
Page 24 - N/A
Page 25 - N/A
Page 26 - N/A
Page 27 - N/A
Page 28 - N/A
Page 29 - N/A
Page 30 - N/A
Page 31 - N/A
Page 32 - N/A
Page 33 - IN WITNESS WHEREOF
Page 34 - APPENDIX A
Page 35 - APPENDIX B
Page 36 - APPENDIX C
Subdocument 4 - EX-23.1 - EX-23.1
Page 1 - Exhibit 23.1